Diagnostic accuracy of the faecal immunochemical test for colorectal cancer in symptomatic patients: comparison with NICE and SIGN referral criteria

被引:70
|
作者
Cubiella, J. [1 ]
Salve, M. [1 ]
Diaz-Ondina, M. [2 ]
Vega, P. [1 ]
Alves, M. T. [3 ]
Iglesias, F. [4 ]
Sanchez, E. [1 ]
Macia, P. [2 ]
Blanco, I. [2 ]
Bujanda, L. [5 ]
Fernandez-Seara, J. [1 ]
机构
[1] Complexo Hosp Univ Ourense, Dept Gastroenterol, Orense 32005, Spain
[2] Complexo Hosp Univ Ourense, Dept Clin Anal, Orense 32005, Spain
[3] Complexo Hosp Univ Ourense, Res Support Unit, Orense 32005, Spain
[4] Complexo Hosp Univ Vigo, Vigo, Spain
[5] Univ Basque Country UPV EHU, Donostia Hosp, Biodonostia Inst, Ctr Invest Biomed Red Enfermedades Hepat & Digest, San Sebastian, Spain
关键词
Colorectal cancer; fecal immunochemical test; colonoscopy; diagnostic accuracy; risk stratification; PRIMARY-CARE; RULE; QUESTIONNAIRE; COLONOSCOPY; GUIDELINES; SYSTEM; AGE;
D O I
10.1111/codi.12569
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim The diagnostic accuracy of the faecal immunochemical test (FIT) at a 100 ng/ml threshold for colorectal cancer (CRC) was compared with National Institute for Health and Care Excellence (NICE) and the Scottish Intercollegiate Guidelines Network (SIGN) referral criteria. Method A multicentre, prospective, blind study of diagnostic tests was carried out in two Spanish health areas. In 787 symptomatic patients referred for a diagnostic colonoscopy, we determined whether patients met NICE and SIGN referral criteria. All patients performed one FIT determination (OCsensor (TM)). The sensitivity and specificity for CRC detection were determined with McNemar's test. The diagnostic odds ratio as well as the number needed to scope (NNS) to detect a CRC were calculated. Results We detected CRC in 97 (12.3%) patients; 241 (30.6%) had an FIT >= 100 ng/ml and 300 (38.1%) and 473 (60.1%) met NICE and SIGN referral criteria. The FIT had a higher sensitivity for CRC detection than NICE criteria (87.6%, 61.9%; P < 0.001) and SIGN criteria (82.5%; P = 0.4). The specificity of FIT was also higher than NICE and SIGN criteria (77.4%, 65.2%, 42.7%; P < 0.001). The odds ratios of FIT, NICE and SIGN criteria for the diagnosis of CRC were 24.24 (95% CI 12.91-45.53), 3.04 (95% CI 1.96-4.71) and 3.51 (95% CI 2.03-6.06). The NNS to detect a CRC in individuals with an FIT = 100 ng/ml was 2.83 (95% CI 2.4-3.41) and in individuals who met NICE and SIGN criteria it was 5 (95% CI 3.98-6.37) and 5.95 (95% CI 4.85-7.35). Conclusion Our study suggests that FIT is more accurate for the detection of CRC than the current NICE and SIGN referral criteria in symptomatic patients referred for colonoscopy.
引用
收藏
页码:O273 / O282
页数:10
相关论文
共 50 条
  • [21] The Fas Track F T study: diagnostic accuracy of faecal immunochemical test for haemoglobin in patients with suspected colorectal cancer
    Turvill, James L.
    Turnock, Daniel
    Cottingham, Dan
    Haritakis, Monica
    Jeffery, Laura
    Girdwood, Annabelle
    Hearfield, Tom
    Mitchell, Alex
    Keding, Ada
    BRITISH JOURNAL OF GENERAL PRACTICE, 2021, 71 (709): : E643 - E651
  • [22] Faecal Immunochemical Testing in Symptomatic Primary Care Patients: A Diagnostic Accuracy Study
    Ball, Alex J.
    Ray, Meghna
    Manji, Arif
    Aziz, Imran
    Sargur, Ravishankar B.
    Kurien, Matthew
    EUROPEAN JOURNAL OF CANCER CARE, 2024, 2024
  • [23] Comparison of a peanut agglutinin test and an immunochemical faecal occult blood test in detecting colorectal neoplasia in symptomatic patients
    Vironen, J
    Kellokumpu, S
    Andersson, LC
    Kellokumpu, I
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2004, 64 (02): : 140 - 145
  • [24] Colorectal cancer prevalence in faecal immunochemical test non-returners: potential for health inequality in symptomatic referral pathways
    Gerrard, Adam D.
    Coxon, Jonty
    Maeda, Yasuko
    Theodoratou, Evropi
    Dunlop, Malcolm G.
    Din, Farhat V. N.
    BJS OPEN, 2024, 8 (05):
  • [25] Proton pump inhibitors reduce the accuracy of faecal immunochemical test for detecting advanced colorectal neoplasia in symptomatic patients
    Rodriguez-Alonso, Lorena
    Rodriguez-Moranta, Francisco
    Arajol, Claudia
    Gilabert, Pau
    Serra, Katja
    Martin, Albert
    Ibanez-Sanz, Gemma
    Moreno, Victor
    Guardiola, Jordi
    PLOS ONE, 2018, 13 (08):
  • [27] UNDETECTABLE FAECAL IMMUNOCHEMICAL TEST FOR HAEMOGLOBIN EXCLUDES COLORECTAL CANCER IN SYMPTOMATIC PATIENTS: A PROSPECTIVE UK STUDY
    Widlak, M. M.
    Thomas, C. L.
    Thomas, M. G.
    Tomkins, C.
    Smith, S.
    Darby, C.
    O'Connell, N.
    Wurie, S.
    Burns, L.
    Harmston, C.
    Evans, C.
    Nwokolo, C. U.
    Singh, B.
    Arasaradnam, R. P.
    GUT, 2017, 66 : A30 - A31
  • [28] Faecal immunochemical testing (FIT) for colorectal cancer in symptomatic primary care patients
    Hunt, N.
    Allcock, R.
    Myers, M.
    CLINICA CHIMICA ACTA, 2019, 493 : S153 - S153
  • [29] Introduction of an integrated primary care faecal immunochemical test referral pathway for patients with suspected colorectal cancer symptoms
    Delisle, Theo Georgiou
    D'Souza, Nigel
    Tan, Jessica
    Najdawi, Ahmad
    Chen, Michelle
    Ward, Helen
    Abulafi, Muti
    COLORECTAL DISEASE, 2022, 24 (12) : 1526 - 1534
  • [30] The state of the faecal immunochemical test in symptomatic patients in the UK
    Abulafi, Muti
    D'Souza, Nigel
    ANNALS OF THE ROYAL COLLEGE OF SURGEONS OF ENGLAND, 2022, 104 (04) : 240 - 241